APO Research
Talk to an analyst

APO RESEARCH · REPORT

Breakthrough Therapy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Breakthrough Therapy Drugs Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchBreakthrough Therapy Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Breakthrough Therapy Drugs Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Breakthrough Therapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Breakthrough Therapy Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Breakthrough Therapy Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Breakthrough Therapy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Breakthrough Therapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Breakthrough Therapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Breakthrough Therapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Breakthrough Therapy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Breakthrough Therapy Drugs market include Novartis, Merck, Pfizer, AbbVie, Vertex Pharmaceuticals Incorporated, Gilead, Genentech and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Breakthrough Therapy Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Breakthrough Therapy Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Breakthrough Therapy Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Breakthrough Therapy Drugs market.

Breakthrough Therapy Drugs Segment by Company

Novartis

Merck

Pfizer

AbbVie

Vertex Pharmaceuticals Incorporated

Gilead

Genentech

Bristol-Myers Squibb Company

Breakthrough Therapy Drugs Segment by Type

Oncology

Neurology

Anti-Viral

Others

Breakthrough Therapy Drugs Segment by Application

Ambulatory Services

Hospitals

Clinics

Breakthrough Therapy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Breakthrough Therapy Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Breakthrough Therapy Drugs key companies, revenue, market share, and recent developments.

3. To split the Breakthrough Therapy Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Breakthrough Therapy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Breakthrough Therapy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Breakthrough Therapy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Breakthrough Therapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Breakthrough Therapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Breakthrough Therapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Breakthrough Therapy Drugs industry.

Chapter 3: Detailed analysis of Breakthrough Therapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Breakthrough Therapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Breakthrough Therapy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Breakthrough Therapy Drugs Industry Trends Table 2. Breakthrough Therapy Drugs Industry Drivers Table 3. Breakthrough Therapy Drugs Industry Opportunities and Challenges Table 4. Breakthrough Therapy Drugs Industry Restraints Table 5. Global Breakthrough Therapy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Breakthrough Therapy Drugs Revenue Share by Company (2021-2026) Table 7. Global Breakthrough Therapy Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Breakthrough Therapy Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Breakthrough Therapy Drugs Company, Product Type & Application Table 10. Global Breakthrough Therapy Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Breakthrough Therapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oncology Table 15. Significant Companies of Neurology Table 16. Significant Companies of Anti-Viral Table 17. Significant Companies of Others Table 18. Global Breakthrough Therapy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Breakthrough Therapy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Breakthrough Therapy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Breakthrough Therapy Drugs Sales Value Share by Type (2021-2026) Table 22. Global Breakthrough Therapy Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Ambulatory Services Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Global Breakthrough Therapy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Breakthrough Therapy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Breakthrough Therapy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Breakthrough Therapy Drugs Sales Value Share by Application (2021-2026) Table 30. Global Breakthrough Therapy Drugs Sales Value Share by Application (2027-2032) Table 31. Global Breakthrough Therapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Breakthrough Therapy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Breakthrough Therapy Drugs Sales Value Share by Region (2021-2026) Table 34. Global Breakthrough Therapy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Breakthrough Therapy Drugs Sales Value Share by Region (2027-2032) Table 36. Global Breakthrough Therapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Breakthrough Therapy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Breakthrough Therapy Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Breakthrough Therapy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Breakthrough Therapy Drugs Sales Value Market Share by Country (2027-2032) Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis Breakthrough Therapy Drugs Product Portfolio Table 45. Novartis Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Merck Breakthrough Therapy Drugs Product Portfolio Table 50. Merck Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pfizer Breakthrough Therapy Drugs Product Portfolio Table 55. Pfizer Recent Development Table 56. AbbVie Company Information Table 57. AbbVie Business Overview Table 58. AbbVie Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. AbbVie Breakthrough Therapy Drugs Product Portfolio Table 60. AbbVie Recent Development Table 61. Vertex Pharmaceuticals Incorporated Company Information Table 62. Vertex Pharmaceuticals Incorporated Business Overview Table 63. Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Product Portfolio Table 65. Vertex Pharmaceuticals Incorporated Recent Development Table 66. Gilead Company Information Table 67. Gilead Business Overview Table 68. Gilead Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Gilead Breakthrough Therapy Drugs Product Portfolio Table 70. Gilead Recent Development Table 71. Genentech Company Information Table 72. Genentech Business Overview Table 73. Genentech Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Genentech Breakthrough Therapy Drugs Product Portfolio Table 75. Genentech Recent Development Table 76. Bristol-Myers Squibb Company Company Information Table 77. Bristol-Myers Squibb Company Business Overview Table 78. Bristol-Myers Squibb Company Breakthrough Therapy Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bristol-Myers Squibb Company Breakthrough Therapy Drugs Product Portfolio Table 80. Bristol-Myers Squibb Company Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Breakthrough Therapy Drugs Product Image Figure 2. Global Breakthrough Therapy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Breakthrough Therapy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Breakthrough Therapy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oncology Image Figure 8. Neurology Image Figure 9. Anti-Viral Image Figure 10. Others Image Figure 11. Global Breakthrough Therapy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Breakthrough Therapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Breakthrough Therapy Drugs Sales Value Share by Type (2021-2032) Figure 14. Ambulatory Services Image Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Global Breakthrough Therapy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Breakthrough Therapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Breakthrough Therapy Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Breakthrough Therapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Breakthrough Therapy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Breakthrough Therapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Breakthrough Therapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Breakthrough Therapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Breakthrough Therapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Breakthrough Therapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Breakthrough Therapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Breakthrough Therapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Breakthrough Therapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Breakthrough Therapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Breakthrough Therapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Oncology
  • Neurology
  • Anti-Viral
  • Others
Applications
  • Ambulatory Services
  • Hospitals
  • Clinics
Companies covered
  • Novartis
  • Merck
  • Pfizer
  • AbbVie
  • Vertex Pharmaceuticals Incorporated
  • Gilead
  • Genentech
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Breakthrough Therapy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Breakthrough Therapy Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Breakthrough Therapy Drugs Market Dynamics
  1. 2.1 Breakthrough Therapy Drugs Industry Trends
  2. 2.2 Breakthrough Therapy Drugs Industry Drivers
  3. 2.3 Breakthrough Therapy Drugs Industry Opportunities and Challenges
  4. 2.4 Breakthrough Therapy Drugs Industry Restraints
3 Breakthrough Therapy Drugs Market by Company
  1. 3.1 Global Breakthrough Therapy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Breakthrough Therapy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Breakthrough Therapy Drugs Company Ranking (2024-2026)
  4. 3.4 Global Breakthrough Therapy Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Breakthrough Therapy Drugs Company Product Type and Application
  6. 3.6 Global Breakthrough Therapy Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Breakthrough Therapy Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Breakthrough Therapy Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Breakthrough Therapy Drugs Market by Type
  1. 4.1 Breakthrough Therapy Drugs Type Introduction
  2. 4.1.1 Oncology
  3. 4.1.2 Neurology
  4. 4.1.3 Anti-Viral
  5. 4.1.4 Others
  6. 4.2 Global Breakthrough Therapy Drugs Sales Value by Type
  7. 4.2.1 Global Breakthrough Therapy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Breakthrough Therapy Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Breakthrough Therapy Drugs Sales Value Share by Type (2021-2032)
5 Breakthrough Therapy Drugs Market by Application
  1. 5.1 Breakthrough Therapy Drugs Application Introduction
  2. 5.1.1 Ambulatory Services
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.2 Global Breakthrough Therapy Drugs Sales Value by Application
  6. 5.2.1 Global Breakthrough Therapy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Breakthrough Therapy Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Breakthrough Therapy Drugs Sales Value Share by Application (2021-2032)
6 Breakthrough Therapy Drugs Regional Value Analysis
  1. 6.1 Global Breakthrough Therapy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Breakthrough Therapy Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Breakthrough Therapy Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Breakthrough Therapy Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Breakthrough Therapy Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Breakthrough Therapy Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Breakthrough Therapy Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Breakthrough Therapy Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Breakthrough Therapy Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Breakthrough Therapy Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Breakthrough Therapy Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Breakthrough Therapy Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Breakthrough Therapy Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Breakthrough Therapy Drugs Sales Value Share by Country, 2025 VS 2032
7 Breakthrough Therapy Drugs Country-level Value Analysis
  1. 7.1 Global Breakthrough Therapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Breakthrough Therapy Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Breakthrough Therapy Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Breakthrough Therapy Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Breakthrough Therapy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Breakthrough Therapy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Breakthrough Therapy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Breakthrough Therapy Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Breakthrough Therapy Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Breakthrough Therapy Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Breakthrough Therapy Drugs Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Vertex Pharmaceuticals Incorporated
  26. 8.5.1 Vertex Pharmaceuticals Incorporated Company Information
  27. 8.5.2 Vertex Pharmaceuticals Incorporated Business Overview
  28. 8.5.3 Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Product Portfolio
  30. 8.5.5 Vertex Pharmaceuticals Incorporated Recent Developments
  31. 8.6 Gilead
  32. 8.6.1 Gilead Company Information
  33. 8.6.2 Gilead Business Overview
  34. 8.6.3 Gilead Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead Breakthrough Therapy Drugs Product Portfolio
  36. 8.6.5 Gilead Recent Developments
  37. 8.7 Genentech
  38. 8.7.1 Genentech Company Information
  39. 8.7.2 Genentech Business Overview
  40. 8.7.3 Genentech Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genentech Breakthrough Therapy Drugs Product Portfolio
  42. 8.7.5 Genentech Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company Breakthrough Therapy Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company Breakthrough Therapy Drugs Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst